Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05177536 · ClinicalTrials.gov registry record · Phase 2

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by University of Nebraska.

Active
Registry status
Phase 2
Development phase
40
Enrollment target
2
Study locations

NCT05177536 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by University of Nebraska. The registered enrollment target is 40 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05177536, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by University of Nebraska.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

Lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) is standard of care for patients with multiple myeloma. However, nearly all patients will experience disease relapse and lenalidomide's toxicity profile leads to treatment discontinuation in 30% of patients after one year. Iberdomide is a novel potent cereblon E3 ligase modulator with a favorable side effect profile. Investigators hypothesize that iberdomide maintenance therapy may result in at least 80% of subjects completing one year of maintenance. This study will determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Around day 100 after ASCT, patients will be assessed to determine study eligibility. Enrolled participants will take iberdomide pills by mouth on days 1-21 of each 28 day cycle. Physical exams, well-being status and blood and/or urine sampling will be conducted and evaluated before each cycle. Treatment will continue until disease progression or toxicity. Follow-up visits with similar testing will occur every 12 weeks until disease relapse or progression or another treatment for the disease is begun.The results from this study will inform the feasibility of pursuing a study comparing iberdomide to lenalidomide maintenance post-ASCT.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Iberdomide

Study Locations (2)

Nebraska

  • University of Nebraska Medical Center - Omaha

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2022-04-15
Est. Completion 2031-01
Phase Phase 2

Sponsor

University of Nebraska

407 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05177536

The ClinicalTrials.gov registry entry for NCT05177536 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Iberdomide is the first listed.

NCT05177536 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Nebraska, New York.

Frequently Asked Questions

What is clinical trial NCT05177536 about?

NCT05177536 is a clinical study titled "Iberdomide Maintenance Therapy in Patients With Multiple Myeloma". Lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) is standard of care for patients with multiple myeloma. However, nearly all patients will experience disease relapse and lenalidomide's toxicity profile leads to treatment discontinuation in 30% of patients after one y...

What is the current status of trial NCT05177536?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-04-15. Estimated completion is 2031-01.

What conditions does trial NCT05177536 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05177536?

The interventions under investigation include: Iberdomide (DRUG).

Who is sponsoring clinical trial NCT05177536?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05177536 being conducted?

This trial has 2 study locations across Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Nebraska

All trials with a study site in Nebraska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.